Gene Therapy Increased Key Protein in FTD Patients
A new investigational therapy for frontotemporal dementia shows potential for boosting progranulin levels.
Updated on Oct. 8, 2026 in Alzheimer’s
Live Poll
Are recent scientific breakthroughs making effective treatments for neurodegenerative conditions more accessible to the public?
Preliminary data from the ASPIRE-FTD trial indicates that a gene therapy, AVB-101, successfully increased progranulin levels in the cerebrospinal fluid of study participants. This investigational approach is being studied in patients with FTD-GRN, a condition characterized by a deficiency of this essential protein.
Why it matters
Patients with FTD-GRN currently lack effective ways to address the significant protein deficiency that drives brain cell dysfunction in this form of dementia. These early results offer a potential mechanism to restore critical protein levels directly in the brain.
In the ongoing ASPIRE-FTD trial of 17 patients, researchers observed a dose-dependent increase in cerebrospinal fluid progranulin at 12 weeks. While early results are encouraging, the trial is still in the preliminary stages of evaluating safety and biological activity.
The players
AviadoBio
A biotechnology company headquartered in London that focuses on developing gene therapies for neurodegenerative conditions like frontotemporal dementia.
The details
AVB-101 is delivered via MRI-guided stereotactic neurosurgery, where the therapy is infused directly into the thalamus. This method allows the treatment to bypass the blood-brain barrier to reach the frontal and temporal cortex, where it aims to restore the progranulin production that is deficient in patients with FTD-GRN. The study protocol notably does not require patients to undergo immunosuppression.
Timeline
12 weeks: Timeframe used to measure the increase in CSF progranulin levels.
52 weeks: Timeframe used to measure serum neurofilament light chain levels.
Health Landscape
The ASPIRE-FTD trial marks a specific step forward in the shift toward targeted gene-based interventions for genetic forms of dementia. This research aims to address the underlying progranulin deficiency that traditional symptomatic treatments for neurodegeneration cannot correct.
As this therapy is currently in early clinical testing, it is not available for clinical use or at medical centers outside of the study sites. If you or a family member are living with a diagnosis of frontotemporal dementia, it is worth discussing the latest trial updates and eligibility criteria with a neurologist.
The takeaway
The ASPIRE-FTD trial provides preliminary evidence that AVB-101 can increase progranulin levels in patients with a specific genetic form of dementia. Patients and families should continue to monitor updates on this research through their neurologist to understand how it may eventually fit into the clinical landscape.
Further reading
For more information on the management and research of dementia, visit our Alzheimer’s section.
More information
View the complete clinical trial study details on the official registry.
Live Poll
Are recent scientific breakthroughs making effective treatments for neurodegenerative conditions more accessible to the public?
